Spherox

Spherox is a biological treatment for cartilage defects in joints, using autologous chondrocyte spheroids. This EU-origin regenerative therapy is designed for intraarticular use. Ideal for cartilage repair in active patients. Suitable for those seeking advanced joint preservation options.

Spherox is used to treat symptomatic cartilage defects in the knee joint in adults. It is designed for patients who have not responded adequately to conservative treatments. The therapy involves implanting spheroids of a patient’s own cartilage cells into the damaged area. This helps restore the joint surface and improve function. It is particularly suited for focal cartilage lesions.

After treatment with Spherox, patients may experience gradual improvement in joint function and pain relief over several months. The implanted spheroids integrate with existing cartilage, supporting tissue regeneration. Some patients report reduced stiffness and increased mobility. The effects vary based on individual healing responses and the extent of cartilage damage.

Spherox should only be administered by trained medical professionals experienced in cartilage repair procedures. Patients must undergo thorough pre-treatment evaluation to ensure suitability. Post-procedure care includes avoiding high-impact activities during recovery. Follow-up appointments are essential to monitor healing progress and joint function.

As a biological therapy using autologous cells, Spherox has minimal systemic interactions with other medications. However, patients should inform their doctor about all current medications, including supplements. Immunosuppressive drugs may theoretically affect the integration of the implanted cells. No specific drug interactions have been widely reported.